Ionis Pharmaceuticals
IONS
Market cap $6.64B

41.73 USD

-0.65

1.53%

At close Jul 11, 4:00 PM EDT

After hours

41.70

-0.03

0.07%

1 day

-1.53%

5 days

-2.23%

1 month

15.31%

3 months

49.57%

6 months

19.43%

Year to date

20.29%

1 year

-11.79%

5 years

-31.63%

10 years

-22.28%

About: Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.

Employees: 927

Healthcare Biotechnology

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

50% more funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 6 (+2) [Q1 2025]

32% more call options, than puts

Call options by funds: $24.8M | Put options by funds: $18.8M

2.71% more ownership

Funds ownership: 101.62% [Q4 2024] → 104.32% (+2.71%) [Q1 2025]

4% less funds holding

Funds holding: 351 [Q4 2024] → 338 (-13) [Q1 2025]

11% less capital invested

Capital invested by funds: $5.61B [Q4 2024] → $5B (-$606M) [Q1 2025]

13% less first-time investments, than exits

New positions opened: 53 | Existing positions closed: 61

16% less repeat investments, than reductions

Existing positions increased: 102 | Existing positions reduced: 122

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$48

15%

upside

Avg. target

$55

31%

upside

High target

$64

53%

upside

5 analyst ratings

4 positive

80%

1 neutral

20%

0 negative

0%

Barclays Gena Wang	37%upside $57	Overweight Upgraded	1 Jul 2025
HC Wainwright & Co. Mitchell Kapoor	20%upside $50	Buy Reiterated	26 Jun 2025
JP Morgan Jessica Fye	15%upside $48	Neutral Maintained	12 Jun 2025
Guggenheim Debjit Chattopadhyay	53%upside $64	Buy Maintained	1 May 2025
Needham Joseph Stringer	32%upside $55	Buy Maintained	30 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about IONS published over the past 30 days

Zacks Investment Research

Should You Buy Ionis Pharmaceuticals (IONS) After Golden Cross?

After reaching an important support level, Ionis Pharmaceuticals, Inc. (IONS) could be a good stock pick from a technical perspective. IONS recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

Should You Buy Ionis Pharmaceuticals (IONS) After Golden Cross?

Zacks Investment Research

Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last?

Ionis Pharmaceuticals (IONS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last?

Ionis: After Years Of Investment, The Wholly-Owned Payoff Is In Sight

Ionis is transitioning from a licensing model to a commercial-stage biotech, investing heavily in its own drug launches and development pipeline. Upcoming catalysts include donidalorsen's FDA decision and olezarsen's Phase 3 data, both with significant peak sales potential in underserved markets. Despite ongoing losses and commercial execution risks, Ionis' validated platform and differentiated drugs offer compelling long-term growth opportunities.

Ionis: After Years Of Investment, The Wholly-Owned Payoff Is In Sight

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the Phase 1 study of salanersen (ION306/BIIB115), an investigational antisense oligonucleotide (ASO) being developed for the potential treatment of spinal muscular atrophy (SMA). Leveraging the same mechanism of action as SPINRAZA® (nusinersen) but designed to achieve greater potency, salanersen has the potential to achieve high efficacy an.

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results

Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Richard Geary, Ph.D., executive vice president and chief development officer, will retire effective January 2026 and that Holly Kordasiewicz, Ph.D., currently senior vice president, neurology, will succeed him in the role. “Richard has made tremendous contributions to Ionis over his 30-year tenure during which he spearheaded dozens of development programs and brought six innovative medicines throu.

Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the global Phase 3 REVEAL study, which is designed to evaluate the efficacy and safety of ION582, an investigational medicine for the treatment of people living with Angelman syndrome (AS), a serious and rare neurodevelopmental disorder that leads to significant physical and cognitive impairments. “Dosing the first person with Angelman syndrome in our pivota.

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

Zacks Investment Research

Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report?

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?

Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report?

Zacks Investment Research

Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study

Late-stage data shows that treatment with an 80mg dose of IONS' Tryngolza achieved a 61% placebo-adjusted reduction in triglyceride levels in six months.

Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study

Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the Essence study of olezarsen in people with moderate hypertriglyceridemia (fasting triglycerides ≥150 mg/dL to

Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides

Ionis to host 2025 virtual Annual Meeting of Stockholders

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2025 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 5, 2025. The agenda for the event is as follows: 5:00 p.m. – 5:15 p.m. ET (2:00 p.m. – 2:15 p.m. PT) – Virtual Annual Meeting of Stockholders All stockholders of record at the close of business on April 7, 2025, are invited to participate in the virtual Annual Meeting we.

Ionis to host 2025 virtual Annual Meeting of Stockholders

See News Rankings

Charts implemented using Lightweight Charts™